Pidilizumab
From Wikipedia the free encyclopedia
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | DLL1 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6424H9920N1704O2002S48 |
| Molar mass | 144594.83 g·mol−1 |
Pidilizumab (formerly CT-011) is a monoclonal antibody being developed by Medivation for the treatment of cancer and infectious diseases.[1][2] Pidilizumab was originally thought to bind to the PD-1 immune checkpoint molecule, however, recent evidence suggests that Delta-like 1 (DLL1) is its primary binding target while binding to PD-1 is secondary and restricted to non-glycosylated and hypoglycosylated forms of this molecule.[3] Pidilizumab causes in the attenuation of apoptotic processes in lymphocytes, primarily effector/memory T cells.
Clinical trials
[edit]It had encouraging results by 2011 from phase II clinical trials for diffuse large B-cell lymphoma.[4] A phase II open-label study in combination for relapsed follicular lymphoma found good results compared to usual response rates. A phase I/II open label study in pediatric patients with a rare form of brain cancer, diffuse intrinsic pontine glioma, found improvement in overall survival compared to expected outcome.[citation needed] An add-on trial for multiple myeloma is ongoing.[5]
References
[edit]- ^ Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, et al. (January 2014). "Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial". The Lancet. Oncology. 15 (1): 69–77. doi:10.1016/S1470-2045(13)70551-5. PMC 3922714. PMID 24332512.
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Pidilizumab, American Medical Association- needs login.
- ^ Carroll J (26 January 2016). "Anti-PD-1? Well, no, says Medivation as a partial hold forces a halt to 'pivotal' cancer study". Fierce Biotech.
- ^ "Teva Invests $19M More in CureTech After Positive Phase II DLBCL Data". Genetic Engineering & Biotechnology News. September 2011.
- ^ Clinical trial number NCT02077959 for "Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma" at ClinicalTrials.gov
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |